This Article Full Text Full Text (PDF) All Versions of this Article: bjo.2007.127902v1 92/2/210    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goverdhan, S V Articles by Lochhead, J Search for Related Content PubMed PubMed Citation Articles by Goverdhan, S V Articles by Lochhead, J Topic Collections Related Article

Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration

Ophthalmology Department, St Mary’s Hospital, Newport, Isle of Wight, UK

Correspondence to:
Mr J Lochhead, Consultant Ophthalmologist, Department of Ophthalmology, St Mary’s Hospital, Newport PO30 5TG, Isle of Wight, UK; jonathan.lochhead{at}iow.nhs.uk

Objective: To report the occurrence of submacular haemorrhages following intravitreal bevacizumab for occult choroidal neovascularisation (CNV) in age-related macular degeneration (AMD).

Methods: Retrospective chart review of 53 patients with occult CNV who had received intravitreal bevacizumab 1.25 mg. Analysis was done in three groups based on mean CNV lesion size: <10 mm² (n = 17), 10 to <15 mm² (n = 17) and 15 mm² (n = 18). ETDRS derived acuity, incidence of fresh macular haemorrhages and haemorrhage size (pre-existing or fresh) were documented and analysed.

Results: The median injection number was 1.0 (range: 1 to 3) with a minimum follow-up of 6 months (range: 4 to 12 months). The mean presenting size of occult lesions was 13.4 mm² (range: 3.0 to 30.3 mm²). Submacular fresh haemorrhages were seen in the absence of pre-existing haemorrhage in four out of 10 patients in the 15 mm² CNV size group (40%) but none in the remaining groups with CNV sizes <15 mm² (OR = 20.1, p = 0.01, 95% CI = 0.99 to 409.3). These haemorrhages developed at a median of 14 days.

Conclusions: Submacular haemorrhages seem to be a significant adverse event following intravitreal bevacizumab in large occult choroidal neovascularisation and may affect visual outcomes. Prospective studies are required to establish the optimal dose of bevacizumab for larger lesion sizes or to identify the most appropriate anti-VEGF agent in large occult CNV with fibrovascular and serous PED lesions.

Related Article

At a glance

Harminder S Dua and Arun D Singh, Editors-in
Br. J. Ophthalmol. 2008 92: 159. [Extract] [Full Text] [PDF]